Search

Displaying results 3671 - 3680 of 10000 in total
  1. Drug

    Metyrosine

    go.drugbank.com/drugs/DB00765
    ApprovedInvestigational

    An inhibitor of the enzyme tyrosine 3-monooxygenase, and consequently of the synthesis of catecholamines.

  2. Drug

    Mirdametinib

    go.drugbank.com/drugs/DB07101
    ApprovedInvestigational

    Mirdametinib is a mitogen-activated protein kinase (MAP2K, MEK, MAPKK) inhibitor. On February 11, 2025, mirdametinib was approved by the FDA for the treatment of neurofibromatosis type 1 (NF1). … [L52485] NF1 is an autosomal-dominant genetic condition caused by loss-of-function variants in the _NF1_ tumour suppressor gene,[A265065,A265070] leading to neurofibromin dysfunction and aberrant activation

  3. Target

    TIR domain-containing adapter molecule 1

    go.drugbank.com/bio_entities/BE0016552
    TargetHumans

    Involved in innate immunity against invading pathogens. Adapter used by TLR3, TLR4 (through TICAM2) and TLR5 to mediate NF-kappa-B and interferon-regulatory factor (IRF) activation, and to induce apoptosis (PubMed:12471095, PubMed:125390...

    Synonyms: Toll-interleukin-1 receptor domain-containing adapter protein inducing interferon beta
  4. Drug

    Levamlodipine

    go.drugbank.com/drugs/DB09237
    ApprovedInvestigational

    Levamlodipine, also known as S-amlodipine, is a pharmacologically active enantiomer of [amlodipine], an antihypertensive medication. … [L10833] As a racemic mixture, amlodipine contains (R) and (S)-amlodipine isomers, but only (S)-amlodipine as the active moiety possesses therapeutic activity.

  5. Drug

    Mavacamten

    go.drugbank.com/drugs/DB14921
    ApprovedInvestigational

    Mavacamten is a myosin inhibitor indicated for the treatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (HCM).

  6. Drug

    Pamidronic acid

    go.drugbank.com/drugs/DB00282
    ApprovedInvestigational

    [A203267] The second generation bisphosphonates are less common as third generation bisphosphonates, such as [ibandronic acid], [zoledronic acid], [minodronic acid], and [risedronic acid] are becoming … Pamidronic acid is a second generation, nitrogen containing bisphosphonate similar to [neridronic acid] and [alendronic acid].[A203111] Pamidronic acid was first described in the literature in 1977.

  7. Drug

    Andexanet alfa

    go.drugbank.com/drugs/DB14562
    Approved

    However, the use of these agents is associated with a risk for uncontrollable bleeding episodes that can lead to can cause serious or fatal bleeding. … Andexanet alfa is a recombinant human coagulation Factor Xa that promotes blood coagulation. It was developed by Portola Pharmaceuticals and was approved in in May 2018.

  8. Drug

    C326

    go.drugbank.com/drugs/DB06017
    Experimental

    The drug is composed of an IL-6–binding trimer and a IgG-binding domain. … C326 is an investigational compound under investigation in clinical trial NCT00353756 (Phase 1 Study of Safety and Biological Effects of C326, an Inhibitor of IL-6, in Crohn's Disease) for the treatment

  9. Drug

    Carbenicillin

    go.drugbank.com/drugs/DB00578
    Approved

    Broad-spectrum semisynthetic penicillin derivative used parenterally. It is susceptible to gastric juice and penicillinase and may damage platelet function.

  10. Drug

    Meclofenamic acid

    go.drugbank.com/drugs/DB00939
    ApprovedInvestigationalVet approved

    A non-steroidal anti-inflammatory agent with antipyretic and antigranulation activities. It also inhibits prostaglandin biosynthesis.